Radiopharmaceticals and supples
Ended Awarded Last action
- Contract number
- W81K0024F0147
- Awardee
-
Pharmalucence, Inc. UEI VFG7FHXXAMN3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $40,878
Award facts
- Contract value 100% obligated
- $40,878.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Bliss, TX 79918, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$34,122 | |
| Funding Only Action | $75,000 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a firm fixed-price Blanket Purchase Agreement (BPA) call contract to Pharmalucence, Inc. for radiopharmaceuticals and supplies valued at $40,878.40, with an ultimate completion date of September 30, 2025. The contract, awarded on October 1, 2024, will be performed at Fort Bliss, Texas and carries no set-aside designation, indicating open competition. Pharmalucence, Inc., a specialty pharmaceutical manufacturer registered in SAM.gov since 2001, specializes in producing and distributing generic radiopharmaceutical products for medical diagnostic services, particularly nuclear medicine imaging applications within military healthcare environments.
This contract is executed as a task order under a larger Indefinite Delivery Vehicle (IDV) BPA valued at $1 million to provide radiopharmaceuticals to various military treatment facilities, which runs through September 2025. The Defense Health Agency utilizes these contracts to support the Military Health System's approximately 9.5 million beneficiaries, including active duty personnel and their families. Pharmalucence's radiopharmaceutical supplies support diagnostic imaging for various medical conditions at military treatment facilities, and the company's established federal contracting history and specialized capabilities in this sector demonstrate its ability to meet the Department of Defense's critical medical supply requirements.
Quick answers
Who was awarded contract W81K0024F0147?
W81K0024F0147 was awarded to Pharmalucence, Inc. by Medical Command (Department of the Army) on October 1, 2024.
How much is contract W81K0024F0147 worth?
The government has obligated $40,878 on W81K0024F0147.
Which agency awarded contract W81K0024F0147?
Medical Command (Department of the Army) awarded W81K0024F0147, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0024F0147 an order under another contract?
Yes. W81K0024F0147 is a BPA call under W81K0020A0014, a blanket purchase agreement.
Was contract W81K0024F0147 competed?
The extent of competition for W81K0024F0147 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award